Spine BioPharma, Inc., a development stage company committed to non-opiate, non-surgical therapies for Degenerative Disc ...

Canaccord analyst Kingsley Crane raised the firm’s price target on CrowdStrike (CRWD) to $420 from $370 and keeps a Buy rating on the shares.

Canaccord raised the firm’s price target on Okta (OKTA) to $100 from $94 and keeps a Hold rating on the shares. The firm said they reported ...

Find insight on lithium, lumber, the impact of tariffs and more in the latest Market Talks covering Basic Materials.

Morgan Stanley reaffirmed Tesla as its top pick, maintaining a $430 price target despite mixed analyst ratings. Some firms, ...

TTEC (NASDAQ:TTEC – Free Report) had its target price reduced by Canaccord Genuity Group from $4.50 to $3.50 in a research ...

Salesforce’s Q1 2026 earnings are forecasted at $1.86 per share, according to DA Davidson. The firm maintained a "Neutral" ...

While many of its peers abandon the lithium sector, Green Technology Metals is priming itself for development.

Bank of Montreal (TSE:BMO – Free Report) (NYSE:BMO) had its price target increased by Canaccord Genuity Group from C$154.00 ...

The general mood among these heavyweight investors is divided, with 13% leaning bullish and 72% bearish. Among these notable ...

Fintel reports that on February 28, 2025, Canaccord Genuity downgraded their outlook for ICF International (NasdaqGS:ICFI) ...

Investors can be cautiously optimistic about the year ahead, according to Canaccord Genuity chief investment strategist Tony Brennan, though the risks to global markets aren't inconsiderable.